← Back to Search

Speech Therapy for Down Syndrome

N/A
Recruiting
Led By Stephen Camarata, PhD
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Previous medical identification of Down Syndrome
Chronological age 6-14 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up six months
Awards & highlights

Study Summary

This trial is measuring speech-articulation accuracy and speech intelligibility in children with Down Syndrome to see if a treatment can help improve speech intelligibility.

Who is the study for?
This trial is for children with Down Syndrome aged 6 to 14 who can use at least three-word sentences, as reported by parents. They must pass a hearing test and have no history of seizures, ADHD, apraxia due to neurological disorders, stuttering, autism (as measured by specific diagnostic scales), or severe disruptive behavior.Check my eligibility
What is being tested?
The study tests the effectiveness of a speech therapy called 'Lexically based speech recast' in improving the clarity of speech in children with Down Syndrome. It will assess how well they articulate words and understand vocabulary before and after treatment.See study design
What are the potential side effects?
Since this intervention involves speech therapy techniques without medication or surgery, there are no direct physical side effects expected from participating in this trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Down Syndrome.
Select...
I am between 6 and 14 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~six months
This trial's timeline: 3 weeks for screening, Varies for treatment, and six months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Speech Accuracy
Speech Intelligibility
Secondary outcome measures
Speech Rate

Trial Design

1Treatment groups
Experimental Treatment
Group I: Lexically Based Speech Intelligibility RecastExperimental Treatment1 Intervention
Speech recasts are likely to improve speech intelligibility in Down Syndrome. The goal of this study is to induce change in speech intelligibility in order to study phonological, acoustic and suprasegmental sequelae of improvements in speech.

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
865 Previous Clinical Trials
673,133 Total Patients Enrolled
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
331 Previous Clinical Trials
178,467 Total Patients Enrolled
Stephen Camarata, PhDPrincipal InvestigatorVUMC Dept of Hearing & Speech Sciences
1 Previous Clinical Trials
72 Total Patients Enrolled

Media Library

Lexically based speech recast Clinical Trial Eligibility Overview. Trial Name: NCT05016037 — N/A
Speech Intelligibility Intervention Research Study Groups: Lexically Based Speech Intelligibility Recast
Speech Intelligibility Intervention Clinical Trial 2023: Lexically based speech recast Highlights & Side Effects. Trial Name: NCT05016037 — N/A
Lexically based speech recast 2023 Treatment Timeline for Medical Study. Trial Name: NCT05016037 — N/A
~6 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top